Fine LinesPhase 4NCT07421544
Assess Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines
A Phase 4 study testing Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid in people with Fine Lines and Wrinkle, run by Goldman, Butterwick, Fitzpatrick and Groff at 1 site in United States.
Trial summary
Clinical trial to assess the real-world effectiveness of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid (HA) gel for the treatment of mild-to-moderate facial aging, including volume loss, fine lines, and skin laxity, following treatment administered using routine clinical injection techniques over the course of 60… Read more about this study
- Who is it for?
- Ages 30 to 75 yearsHealthy volunteers can take part
- Conditions the study is for
- Fine Lines, Wrinkle, Facial Laxity
- What is being tested?
- Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Mar 2026to 1 Jul 2026
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 75 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adult subjects aged 30 to 75 years at the time of screening/baseline.
- Fitzpatrick skin types I-VI.
- Investigator classification of the subject as having mild-to-moderate facial aging in at least one (≥1) facial areas, defined as meeting the following scale criteria at screening/baseline:
- Midface Volume Deficit Scale (Appendix A): score of 2-3 Nasolabial Folds Severity Scale (Appendix B): score of 2 or 3
- Willing and able to comply with all study requirements, including scheduled visits, treatment protocol, and follow-up assessments.
- Willing and able to provide written informed consent form and photography release for research, publication, and/or commercial use.
Show all 14Show fewer
- In good general health as determined by the investigator based on medical history and clinical judgment.
- Willing to maintain the study-specified skincare regimen and refrain from initiating new topical or procedural facial treatments during the study period.
- For subjects of childbearing potential, a negative urine pregnancy test at screening/baseline and at all subsequent visits, as applicable.
- Female subjects of childbearing potential must agree to use an acceptable method of contraception throughout the study and must have been using systemic contraception consistently for at least 30 days prior to enrollment, unless they meet criteria for non-childbearing potential.
- Subjects are considered not of childbearing potential if they meet one of the following:
- History of hysterectomy or bilateral oophorectomy, or No menses for at least 12 consecutive months without an alternative medical cause.
- Or, if of childbearing potential, must agree to use an effective form of contraception during the course of the study. Acceptable methods include:
- Oral contraceptive pill, injection, implant, patch, vaginal ring, or intrauterine device (IUD) Intrauterine coil Bilateral tubal ligation Hysterectomy Barrier method used with an additional form of contraception (e.g., spermicide, sponge, or condom) Abstinence (must agree to use a barrier method if sexual activity begins during the study) Partner with a vasectomy (if not, subject must agree to use a barrier methods
Who cannot join
- Prior use of injectable treatments to the face within the past 12 months, including HA fillers and biostimulator injectables, i.e. calcium hydroxyapatite, poly-L-lactic acid (e.g., Sculptra, Radiesse), platelet-rich plasma (PRP), platelet-rich fibrin (PRF) Any facial surgical procedure (e.g., facelift, facial implants) within the past 12 months.
- Use of neuromodulators (e.g., botulinum toxin) to the face or neck within 6 months prior to study enrollment or at any time during the study period.
- Use of dermal fillers of any kind during the study period.
- Use of at-home energy-based devices intended for rejuvenation or fibroblastic/collagen stimulation within 30 days prior to treatment and during the study period.
- Use of systemic retinoids (e.g., isotretinoin) within 3 months prior to enrollment
- Active infection, open wounds, or inflammatory dermatoses (e.g., eczema, psoriasis, dermatitis) in the treatment area.
Show all 18Show fewer
- Plants to become pregnant during the study period, or current breastfeeding.
- Known allergy or hypersensitivity to lidocaine, tetracaine, or other local anesthetics.
- Coagulation disorders or use of anticoagulants or antiplatelet medications that cannot be safely discontinued per investigator discretion.
- History of autoimmune connective tissue diseases (e.g., systemic lupus erythematosus, scleroderma, dermatomyositis).
- Current or recent use (within the past 3 months) of systemic immunosuppressive medications.
- Any uncontrolled systemic condition that may increase risk or interfere with study participation, including but not limited to poorly managed diabetes, thyroid dysfunction, or cardiovascular disease.
- Clinically significant neurological, psychological or psychiatric conditions, or any condition that, in the opinion of the investigator, may interfere with study participation or interpretation of results.
- Current use of tobacco or nicotine-containing products, or use within 6 months prior to enrollment; participants must also agree to abstain from tobacco and nicotine-containing products for the duration of the study.
- Participation in any other interventional clinical study within 30 days prior to enrollment or during the course of this study.
- Unwillingness to refrain from undergoing any additional aesthetic treatments to the face and neck (e.g., lasers, injectables, energy-based devices, cosmeceuticals, etc.) from screening through the end of the study period.
- Use of sunless tanner or have spray tanned in the treatment areas 4 weeks prior to study treatment.
- History of keloids or scarring/tattoos in the treatment area.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
West Dermatology Research Center
San Diego, California, 92121
Andrea Pacheco, 858-657-1004, apacheco@clderm.com
Freia Canals-Cistero, 858-657-1004, freia.canals-cistero@platinumderm.com
About this study
Official title: A Prospective, Phase 4, Multicenter, Open-label Pilot Study of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines
Clinical trial to assess the real-world effectiveness of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid (HA) gel for the treatment of mild-to-moderate facial aging, including volume loss, fine lines, and skin laxity, following treatment administered using routine clinical injection techniques over the course of 60 days.
Read the detailed description
100 patients total who demonstrate mild-to-moderate signs of facial aging, including volume loss, fine lines, and skin laxity will receive up to two treatments with Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid gel. Patients will return for follow up visits at day 14 and day 60 where they will undergo standardized 2D photography, VISIA photography and assessments.
- Conditions
- Fine Lines, Wrinkle, Facial Laxity, Volume Loss
- Being tested
- Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Obagi® Saypha® MagIQ™ Injectable Hyaluronic AcidOther
Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid is a sterile, biodegradable, homogenized and isotonic HA gel that uses an innovative crosslinking technology (MACRO Core Technology) to achieve a stable 3D HA matrix
| Study group | Role | What they receive |
|---|---|---|
| Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid | Experimental | Enrolled subjects will receive Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid Receives: Other: Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid |
What is being measured
The primary outcome is the main question the study is designed to answer.
Physician Global Aesthetic Improvement Scale (PGAIS)
Circle One:
- Very Much Improved
- Much Improved
- Improved
- No Change
- Worse
Measured: Day 14 and Day 60
Secondary outcomes (3)
Subject Global Aesthetic Improvement Scale (SGAIS)
Circle One:
- Very Much Improved
- Much Improved
- Improved
- No Change
- Worse
Measured: Day 14 and Day 60
Midface Volume Deficit Scale
Circle One:
0- None
- Minimal
- Mild
- Moderate
- Significant
- Severe
Measured: Baseline, Day 14, Day 60
Nasolabial Folds Wrinkle Severity Rating Scale
Circle One
- Absent
- Mild
- Moderate
- Severe
- Extreme
Measured: Baseline, Day 14, Day 60
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Feb 2026
- Study start1 Mar 2026 (estimated)
- Primary completion15 May 2026 (estimated)
- Study completion1 Jul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Fine LinesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- All subjects will receive up to two treatments of Obagi® Saypha® MagIQ™ Injectable HA gel to the mid-face and/or nasolabial folds.
- Masking
- None (open label)
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Goldman, Butterwick, Fitzpatrick and Groff
- Sponsor type
- University, hospital or other
- Collaborators
- Obagi
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07421544
- Sponsor's protocol ID
- Obagi-Saypha-MagIQ
- Status last verified
- Feb 2026
- First submitted
- 12 Feb 2026
- Last updated
- 19 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 19 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Phase 4, Multicenter, Open-label Pilot Study of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines
- ClinicalTrials.gov ID
- NCT07421544
- Acronym / sponsor ID
- Obagi-Saypha-MagIQ
- Conditions
- Fine Lines, Wrinkle, Facial Laxity, Volume Loss
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Goldman, Butterwick, Fitzpatrick and GroffUniversity, hospital or other
- Collaborators
- Obagi
- Study start
- 1 Mar 2026 (estimated)
- Primary completion
- 15 May 2026 (estimated)
- Study completion
- 1 Jul 2026 (estimated)
- First posted
- 19 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Clinical trial to assess the real-world effectiveness of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid (HA) gel for the treatment of mild-to-moderate facial aging, including volume loss, fine lines, and skin laxity, following treatment administered using routine clinical injection techniques over the course of 60 days.
Detailed description
100 patients total who demonstrate mild-to-moderate signs of facial aging, including volume loss, fine lines, and skin laxity will receive up to two treatments with Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid gel. Patients will return for follow up visits at day 14 and day 60 where they will undergo standardized 2D photography, VISIA photography and assessments.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- All subjects will receive up to two treatments of Obagi® Saypha® MagIQ™ Injectable HA gel to the mid-face and/or nasolabial folds.
| Arm | Type | Receives |
|---|---|---|
| Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid | Experimental | Other: Obagi® Saypha® MagIQ™ Injectable Hyaluronic AcidEnrolled subjects will receive Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid |
Who may qualify
- Ages
- 30 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (14 listed)
- Adult subjects aged 30 to 75 years at the time of screening/baseline.
- Fitzpatrick skin types I-VI.
- Investigator classification of the subject as having mild-to-moderate facial aging in at least one (≥1) facial areas, defined as meeting the following scale criteria at screening/baseline:
- Midface Volume Deficit Scale (Appendix A): score of 2-3 Nasolabial Folds Severity Scale (Appendix B): score of 2 or 3
- Willing and able to comply with all study requirements, including scheduled visits, treatment protocol, and follow-up assessments.
Key exclusion criteria (18 listed)
- Prior use of injectable treatments to the face within the past 12 months, including HA fillers and biostimulator injectables, i.e. calcium hydroxyapatite, poly-L-lactic acid (e.g., Sculptra, Radiesse), platelet-rich plasma (PRP), platelet-rich fibrin (PRF) Any facial surgical procedure (e.g., facelift, facial implants) within the past 12 months.
- Use of neuromodulators (e.g., botulinum toxin) to the face or neck within 6 months prior to study enrollment or at any time during the study period.
- Use of dermal fillers of any kind during the study period.
- Use of at-home energy-based devices intended for rejuvenation or fibroblastic/collagen stimulation within 30 days prior to treatment and during the study period.
- Use of systemic retinoids (e.g., isotretinoin) within 3 months prior to enrollment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Obagi® Saypha® MagIQ™ Injectable Hyaluronic AcidObagi® Saypha® MagIQ™ Injectable Hyaluronic Acid is a sterile, biodegradable, homogenized and isotonic HA gel that uses an innovative crosslinking technology (MACRO Core Technology) to achieve a stable 3D HA matrix | Other | Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid |
Primary outcome
Physician Global Aesthetic Improvement Scale (PGAIS)
Time frame: Day 14 and Day 60
Circle One: 1. Very Much Improved 2. Much Improved 3. Improved 4. No Change 5. Worse
3 secondary outcomes
Subject Global Aesthetic Improvement Scale (SGAIS)
Time frame: Day 14 and Day 60
Midface Volume Deficit Scale
Time frame: Baseline, Day 14, Day 60
Nasolabial Folds Wrinkle Severity Rating Scale
Time frame: Baseline, Day 14, Day 60
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Feb 2026.
Related trials for Fine Lines
Enrolling by invitation
Efficacy of an LED Mask
Fine Lines and Wrinkles, Skin Health
Recruiting
Efficacy of Topical Niacinamide Riboside on the Signs of Facial Skin Aging
Skin Aging on Face, Skin Care Dermocosmetics
Not yet recruiting
A Clinical Trial to Evaluate the Effects of Naila's Collagen Marine Plus Food Supplement on Skin Hydration, Elasticity, Fine Lines and Wrinkles, and Hair and Nail Health
Skin Aging, Skin Hydration
Not yet recruiting
Examine Impact of Topical Application of Active Versus Placebo on the Skin Microbiome in Sensitive Skin.
Skin, Skin Microbiome
Not yet recruiting
Clinical Trial to Assess the Efficacy and Safety of a Cosmetic Product in Individuals Showing Signs of Cutaneous Aging.
Skin, Skin Ageing
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid in people with Fine Lines and Wrinkle, run by Goldman, Butterwick, Fitzpatrick and Groff at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 19 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Andrea Pacheco (8586571004, apacheco@clderm.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Physician Global Aesthetic Improvement Scale (PGAIS) (time frame: Day 14 and Day 60). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Feb 2026.